RNA interference as a tool for Alzheimer's disease therapy

Antonio Orlacchio, Giorgio Bernardi, Aldo Orlacchio, Sabata Martino

Research output: Contribution to journalArticle

Abstract

RNA interference is a biological process that controls gene silencing in all living cells. Targeting the RNA interference system represents a novel therapeutic strategy able to intercede with multiple disease-related genes and to target many neurodegencrative diseases. Recently, the design of small interfering RNA-selective compounds has become more straightforward because of the significant progress made in predictive modeling for new therapeutic approaches. Although in vivo delivery of RNA interference remains a significant obstacle, new data show that RNAi blocks gene function in vivo, suggesting a potential therapeutic approach for humans. Some groups have demonstrated the efficacy of RNAi therapy in Alzheimer's disease. Results, based on animal models, show a down-regulation of the amyloid precursor protein and a consequent reduction of the amyloid-β peptide accumulation in the brain or the inactivation of P-secretase (BACEI). Indeed, lentiviral vectors expressing siRNAs targeting BACE1 reduce amyloid production and the neurodegencrative and behavioural deficit in APP transgenic mice. This review highlights recent advances in RNA research and focuses on strengths and weaknesses of RNAi compounds in Alzheimer's disease.

Original languageEnglish
Pages (from-to)1166-1176
Number of pages11
JournalMini-Reviews in Medicinal Chemistry
Volume7
Issue number11
DOIs
Publication statusPublished - Nov 2007

Fingerprint

RNA Interference
Alzheimer Disease
RNA
Genes
Amyloid
Amyloid Precursor Protein Secretases
Amyloid beta-Protein Precursor
Biological Phenomena
Therapeutics
Small Interfering RNA
Process control
Gene Silencing
Brain
Animals
Cells
Transgenic Mice
Down-Regulation
Animal Models
Peptides
Research

ASJC Scopus subject areas

  • Chemistry(all)
  • Medicine (miscellaneous)
  • Pharmacology

Cite this

RNA interference as a tool for Alzheimer's disease therapy. / Orlacchio, Antonio; Bernardi, Giorgio; Orlacchio, Aldo; Martino, Sabata.

In: Mini-Reviews in Medicinal Chemistry, Vol. 7, No. 11, 11.2007, p. 1166-1176.

Research output: Contribution to journalArticle

Orlacchio, Antonio ; Bernardi, Giorgio ; Orlacchio, Aldo ; Martino, Sabata. / RNA interference as a tool for Alzheimer's disease therapy. In: Mini-Reviews in Medicinal Chemistry. 2007 ; Vol. 7, No. 11. pp. 1166-1176.
@article{fab033e0f71d4548ac8bc69988ec05b8,
title = "RNA interference as a tool for Alzheimer's disease therapy",
abstract = "RNA interference is a biological process that controls gene silencing in all living cells. Targeting the RNA interference system represents a novel therapeutic strategy able to intercede with multiple disease-related genes and to target many neurodegencrative diseases. Recently, the design of small interfering RNA-selective compounds has become more straightforward because of the significant progress made in predictive modeling for new therapeutic approaches. Although in vivo delivery of RNA interference remains a significant obstacle, new data show that RNAi blocks gene function in vivo, suggesting a potential therapeutic approach for humans. Some groups have demonstrated the efficacy of RNAi therapy in Alzheimer's disease. Results, based on animal models, show a down-regulation of the amyloid precursor protein and a consequent reduction of the amyloid-β peptide accumulation in the brain or the inactivation of P-secretase (BACEI). Indeed, lentiviral vectors expressing siRNAs targeting BACE1 reduce amyloid production and the neurodegencrative and behavioural deficit in APP transgenic mice. This review highlights recent advances in RNA research and focuses on strengths and weaknesses of RNAi compounds in Alzheimer's disease.",
author = "Antonio Orlacchio and Giorgio Bernardi and Aldo Orlacchio and Sabata Martino",
year = "2007",
month = "11",
doi = "10.2174/138955707782331678",
language = "English",
volume = "7",
pages = "1166--1176",
journal = "Mini-Reviews in Medicinal Chemistry",
issn = "1389-5575",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - RNA interference as a tool for Alzheimer's disease therapy

AU - Orlacchio, Antonio

AU - Bernardi, Giorgio

AU - Orlacchio, Aldo

AU - Martino, Sabata

PY - 2007/11

Y1 - 2007/11

N2 - RNA interference is a biological process that controls gene silencing in all living cells. Targeting the RNA interference system represents a novel therapeutic strategy able to intercede with multiple disease-related genes and to target many neurodegencrative diseases. Recently, the design of small interfering RNA-selective compounds has become more straightforward because of the significant progress made in predictive modeling for new therapeutic approaches. Although in vivo delivery of RNA interference remains a significant obstacle, new data show that RNAi blocks gene function in vivo, suggesting a potential therapeutic approach for humans. Some groups have demonstrated the efficacy of RNAi therapy in Alzheimer's disease. Results, based on animal models, show a down-regulation of the amyloid precursor protein and a consequent reduction of the amyloid-β peptide accumulation in the brain or the inactivation of P-secretase (BACEI). Indeed, lentiviral vectors expressing siRNAs targeting BACE1 reduce amyloid production and the neurodegencrative and behavioural deficit in APP transgenic mice. This review highlights recent advances in RNA research and focuses on strengths and weaknesses of RNAi compounds in Alzheimer's disease.

AB - RNA interference is a biological process that controls gene silencing in all living cells. Targeting the RNA interference system represents a novel therapeutic strategy able to intercede with multiple disease-related genes and to target many neurodegencrative diseases. Recently, the design of small interfering RNA-selective compounds has become more straightforward because of the significant progress made in predictive modeling for new therapeutic approaches. Although in vivo delivery of RNA interference remains a significant obstacle, new data show that RNAi blocks gene function in vivo, suggesting a potential therapeutic approach for humans. Some groups have demonstrated the efficacy of RNAi therapy in Alzheimer's disease. Results, based on animal models, show a down-regulation of the amyloid precursor protein and a consequent reduction of the amyloid-β peptide accumulation in the brain or the inactivation of P-secretase (BACEI). Indeed, lentiviral vectors expressing siRNAs targeting BACE1 reduce amyloid production and the neurodegencrative and behavioural deficit in APP transgenic mice. This review highlights recent advances in RNA research and focuses on strengths and weaknesses of RNAi compounds in Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=36749049934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749049934&partnerID=8YFLogxK

U2 - 10.2174/138955707782331678

DO - 10.2174/138955707782331678

M3 - Article

C2 - 18045220

AN - SCOPUS:36749049934

VL - 7

SP - 1166

EP - 1176

JO - Mini-Reviews in Medicinal Chemistry

JF - Mini-Reviews in Medicinal Chemistry

SN - 1389-5575

IS - 11

ER -